Discharge Readmission Analysis and Management in Sepsis (DReAMS-2)
NCT ID: NCT06099756
Last Updated: 2023-11-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
2000 participants
OBSERVATIONAL
2023-10-26
2024-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will allow the study team to follow their health after they are discharged by taking their temperature once a day and placing their index finger over their smartphone camera when prompted by a text message. Participants will receive the text messages twice a day. When the participant receives the text message, they will click on the link and follow the instructions. Instructions include how to long to keep your finger on your phone camera and how to report your daily temperature. Additional questions will also be asked. After 30 days, the text messages will stop, and participation will be complete.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Implementation and Evaluations of Sepsis Watch
NCT03655626
Reducing 30-Day Sepsis Readmissions: Impact of a Post Discharge Education Program
NCT05602896
Early Prediction of Sepsis
NCT04570618
Predict Sepsis; the Predictive Value of Bedside Measures in the Ambulance
NCT03249597
Combined Determination of sTREM-1, PCT and CD64 in Diagnosing Sepsis
NCT02198950
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* The study team member will guide the participant to open the study smartphone app on their phone.
* The app will provide a tutorial on how to take a measurement, after which the participant will complete their first measurement. The Duke research team member will assist the participant to ensure it is taken correctly. The measurement involves taking a video of the participant's fingertip using the app by placing their finger on the smartphone camera and holding their hand flat on a table. The video frames are immediately processed in real-time to extract the blood flow signal. The app automatically uploads the blood flow signal to the Measure Labs cloud backend.
* Once the patient has completed their first measurement, they will be considered enrolled in the study.
* Study team will measure participant's vital signs (heart rate, respiratory rate, blood pressure, temperature, and oxygen saturation) after they have been enrolled into the study.
* A digital thermometer will be sent home with the participants on day of discharge. The app will provide an input for the participant to enter their daily temperature.
Throughout the study, the participant will be expected to place their fingertip on their smartphone camera twice a day and take their temperature once a day. Participants will receive two text messages with a link to enter their temperature, scan their fingertip with their camera, and answer some questions about their current health status. Participation will occur from day of consent to 30 days after patient was enrolled. During the final week of the study, the patient will be asked if they would like to continue receiving text messages for an additional 60 days. If they decline or don't respond, after day 30, participant will no longer receive text messages.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Admitted to the hospital for 48 hours or greater
* Admitted with an index diagnoses of sepsis. We defined sepsis based on the 2018 Centers for Disease Control and Prevention's Adult Sepsis Event (ASE).
\[1\] A subject must have an order for blood cultures, at least 4 qualifying antimicrobial days AND Evidence of at least 1 end organ dysfunction (new vasopressors, initiation of mechanical ventilation, doubling of serum creatinine (or GFR reduction by 50%), total bilirubin ≥ 2.0 mg/dl, an increase by 100% from baseline, platelet count \< 100 cells/ul, and lactate ≥ 2.0.
* The adaptive design will allow the expansion into additional index hospitalization diagnosis (for example, heart failure exacerbation, sickle cell crises, COPD exacerbation, hip fractures, pneumonia, post surgical patients, diabetes mellitus)
Exclusion Criteria
* Patients due to be transferred to another acute care facility
* Participants not proficient with written and spoken English.
* Participants who do not have a smartphone and valid mobile number to receive text messages.
* Participants leaving the hospital against medical advice.
* Participants with essential tremor.
* Participants deemed non-compliant or not suitable for the study due to cognitive impairment or serious mental health conditions as determined by the Principal Investigator.
* Participants unable to independently navigate and operate smartphone applications.
* Participants with diminished decision-making capability.
* Participants likely to not be available to complete all protocol-required procedures (e.g., Clinical Outcome Assessments) to the best of the subject and investigator's knowledge.
* Participants with history or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or study team, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion
* Vulnerable Subjects, this study will not enroll children \< 18 years of age, pregnant women, or prisoners.
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Duke University
OTHER
Measure Labs, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lana Wahid, MD
Role: PRINCIPAL_INVESTIGATOR
Duke University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Duke Regional Hospital
Durham, North Carolina, United States
Duke University Hospital
Durham, North Carolina, United States
Duke Raleigh Hospital
Raleigh, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DReAMS-2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.